Clinical Trial

Burnout, Secondary Traumatic Stress and Inflammatory Biomarkers in ICU Healthcare Workers

Completed
View on ClinicalTrials.gov →
Summary
Healthcare professionals working in intensive care units (ICUs) are frequently exposed to high levels of psychological stress due to critically ill patients, frequent encounters with death, complex clinical decision-making, and prolonged working hours. This environment increases the risk of burnout and secondary traumatic stress, which may not only affect mental well-being but also have measurable physiological consequences. Emerging evidence suggests that chronic psychological stress and burnout may influence immune function through activation of proinflammatory pathways. Elevated levels of inflammatory biomarkers such as C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and neutrophil-to-lymphocyte ratio (NLR) have been associated with stress-related conditions. However, data examining the relationship between burnout, secondary traumatic stress, and inflammatory biomarkers in intensive care healthcare workers remain limited. This cross-sectional observational study aims to investigate the association between burnout and secondary traumatic stress levels, assessed using validated psychometric instruments (Maslach Burnout Inventory and Professional Quality of Life Scale), and inflammatory biomarkers (CRP, IL-6, TNF-α, and NLR) in ICU healthcare workers. Blood samples will be obtained in conjunction with routine annual health screening, and additional serum samples will be collected for biomarker analysis. The study seeks to clarify the psychoneuroimmunological mechanisms underlying occupational stress in critical care settings.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Completed 2026-04-24
Trial Details
NCT Number NCT07437443
Lead Sponsor Elazıg Fethi Sekin Sehir Hastanesi
Conditions Burnout, Secondary Traumatic Stress, Occupational Stress, Inflammation, Critical Care Staff
Enrollment 140 participants
Start Date 2026-02-23
Primary Completion 2026-03-01 (estimated)
Study Completion 2026-03-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-23